C4 Therapeutics Inc Dossier
Qualitative Analysis
Business overview
C4 Therapeutics, Inc. (C4T) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation (TPD) science to create a new generation of medicines. Leveraging its proprietary TORPEDO (Targeted ORiented Protein Degrader Optimizer) platform, the company designs and develops small-molecule medicines, specifically MonoDAC (monovalent) and BIDAC (bivalent) degraders, to target and destroy disease-causing proteins. C4T's pipeline is anchored by its lead clinical program, cemsidomide (formerly CFT7455), an oral IKZF1/3 molecular glue degrader being evaluated for relapsed/refractory multiple myeloma (RRMM). The company also possesses a robust suite of strategic partnerships with global pharmaceutical leaders, including Roche, Biogen, Betta Pharmaceuticals, and Merck KGaA, validating its platform and extending its development capabilities.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Rapidly advancing lead clinical candidate cemsidomide (an oral IKZF1/3 molecular glue degrader) across multiple lines of therapy in multiple myeloma, both as a monotherapy (Phase 2 MOMENTUM trial) and in combination with elranatamab (Phase 1b trial) and other anti-myeloma agents.
Expected impact: Positions cemsidomide as a potential best-in-class, foundational oral therapy for relapsed/refractory multiple myeloma.
Implementing a new internal discovery strategy leveraging the proprietary TORPEDO platform to design and develop small-molecule degraders targeting inflammation, neuroinflammation, and neurodegenerative diseases (INN), with a focus on CNS-penetrant degraders.
Expected impact: Diversifies the pipeline beyond oncology into high-value therapeutic areas with significant unmet medical needs.
Discontinuing the clinical development of EGFR L858R degrader CFT8919 outside of Greater China to focus resources and capital on lead oncology asset cemsidomide and the INN discovery pipeline.
Expected impact: Reduces clinical trial expenses and extends the company's cash runway to the end of 2028.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Expands the long-term partnership to discover and develop degrader-antibody conjugates (DACs) for oncology, combining C4T's TORPEDO platform with Roche's antibody design and conjugation capabilities.
Terms: $20 million upfront payment received in May 2026, with eligibility for over $1 billion in discovery, regulatory, and commercial milestones, plus tiered royalties on future net sales.
Pfizer supplies elranatamab (ELREXFIO), a BCMA CD3-targeted bispecific antibody, for C4T's Phase 1b clinical trial evaluating cemsidomide in combination with elranatamab in relapsed/refractory multiple myeloma.
Terms: Pfizer provides clinical drug supply of elranatamab; other financial terms undisclosed.
Exclusive license for the development and commercialization of EGFR L858R degrader CFT8919 in Greater China, leveraging Betta's regional development capabilities.
Terms: $10 million upfront payment, $25 million equity investment, and eligibility for up to $357 million in potential milestones plus royalties.